China Pharma Holdings financials
$0.6502−9.06%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 | FY20 Dec 31 | FY19 Dec 31 | FY18 Dec 31 | FY17 Dec 31 | FY16 Dec 31 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.1M | $4.5M | $7.0M | $8.1M | $9.6M | $10.9M | $10.9M | $12.3M | $13.2M | $15.6M |
| Gross profit | -$131.9K | -$2.0M | -$281.1K | -$493.9K | $349.3K | $2.0M | $1.5M | $2.0M | $2.5M | $3.2M |
| Gross margin | −3.2% | −43.8% | −4.0% | −6.1% | 3.6% | 18.0% | 13.6% | 16.0% | 18.7% | 20.7% |
| Operating income | -$3.2M | -$4.6M | -$2.8M | -$3.5M | -$2.9M | -$2.6M | -$20.4M | -$10.4M | -$18.7M | -$8.5M |
| Net income | -$3.2M | -$4.7M | -$3.1M | -$4.0M | -$3.4M | -$2.9M | -$20.7M | -$10.8M | -$19.3M | -$9.2M |
| Net margin | −76.9% | −104.6% | −43.9% | −49.0% | −35.3% | −26.4% | −189.5% | −87.2% | −145.9% | −59.0% |
| Diluted EPS | $-0.74 | $-2.71 | $-9.10 | $-37.80 | $-37.00 | $-35.00 | $-240.00 | $-125.00 | $-220.00 | $-105.00 |
| EBITDA | -$1.7M | -$2.0M | $1.8K | -$848.4K | $227.3K | $101.2K | -$463.9K | -$709.6K | -$1.2M | -$1.5M |
| Operating cash flow | $148.3K | -$406.1K | -$699.7K | -$409.5K | -$249.8K | -$42.3K | $608.3K | $1.9M | $841.2K | $2.9M |
| Free cash flow | $88.9K | -$444.5K | -$711.2K | -$409.5K | -$687.9K | -$909.6K | $472.3K | $1.8M | $704.7K | $2.7M |
| Diluted shares | 4.3M | 1.7M | 0.3M | 0.1M | 0.1M | 0.1M | 0.1M | 0.1M | 0.1M | 0.1M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|---|
| Cash & equivalents | $345.1K | $626.9K | $1.4M | $2.0M | $4.9M | $957.7K |
| Short-term investments | $0.00 | $18.6K | $0.00 | $0.00 | — | — |
| Total debt | $3.4M | $3.6M | $4.5M | $8.7M | $9.6M | $5.2M |
| Total assets | $31.0M | $14.9M | $16.5M | $17.8M | $22.6M | $21.1M |
| Total liabilities | $8.3M | $7.1M | $9.0M | $13.5M | $16.6M | $13.1M |
| Shareholders' equity | $22.7M | $7.7M | $7.5M | $4.3M | $6.0M | $8.0M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology